Literature DB >> 21645868

Counterpoint: long-course chemoradiation is preferable in the neoadjuvant treatment of rectal cancer.

Bruce D Minsky1.   

Abstract

There are 2 approaches to preoperative therapy. Short-course (25 Gy in 5 fractions) radiation and long-course (50.4 Gy in 28 fractions) radiation combined with chemotherapy (CMT). Although short-course radiation therapy is used in some European countries, it is not favored in all European countries or North America. Unlike long-course CMT, it cannot be safely combined with adequate doses of systemic concurrent chemotherapy, and, as currently designed, it does not increase sphincter preservation. Long-course CMT remains the preferred regimen for cT3 and/or node-positive disease. With parallel advances in staging, surgery, systemic therapy, and molecular markers, more selective approaches are being investigated.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21645868     DOI: 10.1016/j.semradonc.2011.02.009

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  3 in total

1.  Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer.

Authors:  Jen-Kou Lin; Lin-Kun Lee; Wei-Shone Chen; Tzu-Chen Lin; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Shih-Ching Chang; Yuan-Tzu Lan; Chun-Chi Lin; Chueh-Chuan Yen; Jin-Hwang Liu; Cheng-Hwai Tzeng; Hao-Wei Teng
Journal:  J Gastrointest Surg       Date:  2012-07-26       Impact factor: 3.452

2.  Trends and disparities in the utilization of hypofractionated neoadjuvant radiation therapy for rectal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-08

3.  Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer.

Authors:  Chi Zhang; Liping Xu; Qin Qin; Jia Liu; Xinyu Tang; Nan Jiang; Zhaoyue Zhang; Fei Li; Hongyan Cheng; Jiayan Chen; Xinchen Sun
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.